

# DID YOU KNOW?

PBMs, Plans and Wholesalers Continually Rank Higher on Fortune 500 Lists than Biopharmaceutical Companies

## THE TOP 10

2022

Fortune 500 Rankings

1. Walmart
2. Amazon
3. Apple
4. CVS Health ●
5. UnitedHealth Group ●
6. Exxon Mobil
7. Berkshire Hathaway
8. Alphabet
9. McKesson ●
10. AmerisourceBergen ●

- Health Plan, PBM, Pharmacy
- Health Plan, PBM
- Wholesale Distributor

## FORTUNE

<https://fortune.com/ranking/fortune500/2022/search/>

### PBMs, Plans and Wholesalers Continually Rank Higher on Fortune 500 Lists than Biopharmaceutical Companies

#### TOP RANKED PBMS AND PLANS

4. CVS Health (Caremark and Aetna)
5. UnitedHealth Group (OptumRx)
12. Cigna (Express Scripts)


#### TOP RANKED BIOPHARMA COMPANIES

37. Johnson & Johnson
43. Pfizer
63. AbbVie

### Insurers and PBMs Control Access to Pharmacies and Leverage for Medicine Costs

TOP 3 MARKET SHARE:  
**80%**

- All Other
- OptumRx (UnitedHealth Group)
- Express Scripts
- CVS Health (Caremark)



#### INSURERS DETERMINE:

##### FORMULARY

if a medicine is covered

##### TIER PLACEMENT

patient cost sharing

##### ACCESSIBILITY

utilization management through prior authorization or fail first


##### PROVIDER INCENTIVES

preferred treatment guidelines and pathways

## HOW DOES THE BIOPHARMACEUTICAL INDUSTRY COMPARE TO OTHER INDUSTRIES?

### Biopharmaceutical Profits Are in Line With Those of Other Industries

#### AVERAGE ECONOMIC PROFIT FOR SELECTED INDUSTRIES, 2019-2021\*



Accounting for the significant risk and capital investments required to develop medicines, biopharmaceutical industry profits are average among industries.

\*Economic profits are accounting profits minus capital expenses.

†Represents the weighted average of pharmaceuticals (8.2%) and biotechnology (2.2%), which are listed as separate industries in the source data.

Source: Adapted from R. Manning and A. Subramaniam, Intensity, LLC. Economic Profitability of the Biopharmaceutical Industry, 2022.

<https://intensity.com/news/economic-profitability-of-the-biopharmaceutical-industry-2022>